Geriatric risk model for older patients with diffuse large B-cell lymphoma (GERIAD): a prospective multicenter cohort study
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Optimal risk stratification based on simplified geriatric assessment to predict treatment-related toxicity and survival needs to be clarified in older patients with diffuse large B-cell lymphoma (DLBCL). Methods: This multicenter prospective cohort study enrolled newly diagnosed patients with DLBCL (≥ 65 yr) between September 2015 and April 2018. A simplified geriatric assessment was performed at baseline using Activities of Daily Living (ADL), Instrumental ADL (IADL), and Charlson’s Comorbidity Index (CCI). The primary endpoint was event-free survival (EFS). Results: The study included 249 patients, the median age was 74 years (range, 65-88), and 125 (50.2%) were female. In multivariable Cox analysis, ADL, IADL, CCI, and age were independent factors for EFS; an integrated geriatric score was derived and the patients stratified into three geriatric categories: fit (n = 162, 65.1%), intermediate-fit (n = 25, 10.0%), and frail (n = 62, 24.9%). The established geriatric model was significantly associated with EFS (fit vs. intermediate-fit, HR 2.61, p < 0.001; fit vs. frail, HR 4.61, p < 0.001) and outperformed each covariate alone or in combination. In 87 intermediate-fit or frail patients, the relative doxorubicin dose intensity (RDDI) ≥ 62.4% was significantly associated with worse EFS (HR, 2.15, 95% CI 1.30–3.53, p = 0.002). It was related with a higher incidence of grade ≥ 3 symptomatic non-hematologic toxicities (63.2% vs. 27.8%, p < 0.001) and earlier treatment discontinuation (34.5% vs. 8.0%, p < 0.001) in patients with RDDI ≥ 62.4% than in those with RDDI < 62.4%. Conclusions: This model integrating simplified geriatric assessment can risk-stratify older patients with DLBCL and identify those who are highly vulnerable to standard dose-intensity chemoimmunotherapy.
Abstract
Background/Aims: Optimal risk stratification based on simplified geriatric assessment to predict treatment-related toxicity and survival needs to be clarified in older patients with diffuse large B-cell lymphoma (DLBCL). Methods: This multicenter prospective cohort study enrolled newly diagnosed patients with DLBCL (≥ 65 yr) between September 2015 and April 2018. A simplified geriatric assessment was performed at baseline using Activities of Daily Living (ADL), Instrumental ADL (IADL), and Charlson’s Comorbidity Index (CCI). The primary endpoint was event-free survival (EFS). Results: The study included 249 patients, the median age was 74 years (range, 65-88), and 125 (50.2%) were female. In multivariable Cox analysis, ADL, IADL, CCI, and age were independent factors for EFS; an integrated geriatric score was derived and the patients stratified into three geriatric categories: fit (n = 162, 65.1%), intermediate-fit (n = 25, 10.0%), and frail (n = 62, 24.9%). The established geriatric model was significantly associated with EFS (fit vs. intermediate-fit, HR 2.61, p < 0.001; fit vs. frail, HR 4.61, p < 0.001) and outperformed each covariate alone or in combination. In 87 intermediate-fit or frail patients, the relative doxorubicin dose intensity (RDDI) ≥ 62.4% was significantly associated with worse EFS (HR, 2.15, 95% CI 1.30–3.53, p = 0.002). It was related with a higher incidence of grade ≥ 3 symptomatic non-hematologic toxicities (63.2% vs. 27.8%, p < 0.001) and earlier treatment discontinuation (34.5% vs. 8.0%, p < 0.001) in patients with RDDI ≥ 62.4% than in those with RDDI < 62.4%. Conclusions: This model integrating simplified geriatric assessment can risk-stratify older patients with DLBCL and identify those who are highly vulnerable to standard dose-intensity chemoimmunotherapy.
참고문헌 (32)
- Lee H, "Nationwide statistical analysis of lymphoid malignancies in Korea", Cancer Res Treat, 50, pp.222~238 (2018)
- Tucci A, "A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy", Cancer, 115, pp.4547~4553 (2009)
- Olivieri A, "Tailored therapy in an unselected population of 91 elderly patients with DLBCL prospectively evaluated using a simplified CGA", Oncologist, 17, pp.663~672 (2012)
- Spina M, "Modulated chemotherapy according to modified comprehensive geriatric assessment in 100 consecutive elderly patients with diffuse large B-cell lymphoma", Oncologist, 17, pp.838~846 (2012)
- Tucci A, "Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma : a prospective multicenter evaluation in 173 patients by the Lymphoma Italian Foundation(FIL)", Leuk Lymphoma, 56, pp.921~926 (2015)
- Liu H, "Validation and refinement of the age, comorbidities, and albumin index in elderly patients with diffuse large B-cell lymphoma : an effective tool for comprehensive geriatric assessment", Oncologist, 23, pp.722~729 (2018)
- Wieringa A, "Comorbidity is an independent prognostic factor in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP : a population-based cohort study", Br J Haematol, 165, pp.489~496 (2014)
- Kobayashi Y, "Charlson Comorbidity Index is an independent prognostic factor among elderly patients with diffuse large B-cell lymphoma", J Cancer Res Clin Oncol, 137, pp.1079~1084 (2011)
- DuMontier C, "Arti Hurria and the progress in integrating the geriatric assessment into oncology : Young International Society of Geriatric Oncology review paper", J Geriatr Oncol, 11, pp.203~211 (2020)
- Bang HJ, "Geriatric functional assessment for decision-making on adjuvant chemotherapy in older colon cancer patients", Korean J Intern Med, 37, pp.660~672 (2022)
- Choi JY, "Assessing frailty using comprehensive geriatric assessment in older patients with hematologic malignancy", Blood Res, 57(S1), pp.1~5 (2022)
- Merli F, "Simplified geriatric assessment in older patients with diffuse large B-cell lymphoma : the prospective elderly project of the Fondazione Italiana Linfomi", J Clin Oncol, 39, pp.1214~1222 (2021)
- Eyre TA, "Results of a large retrospective analysis of the effect of intended dose intensity of R-CHOP on outcome in a cohort of consecutive, unselected elderly patients with de novo diffuse large B cell lymphoma", Br J Haematol, 173, pp.487~491 (2016)
- Eyre TA, "Impact of intended and relative dose intensity of R-CHOP in a large, consecutive cohort of elderly diffuse large B-cell lymphoma patients treated with curative intent : no difference in cumulative incidence of relapse comparing patients by age", J Intern Med, 285, pp.681~692 (2019)
- Vidal L, "The effect of R-CHOP dose reduction on overall survival of elderly patients with DLBCL-comparative study", Leuk Lymphoma, 59, pp.904~910 (2018)
- Juul MB, "Treatment strategies and outcomes in diffuse large B-cell lymphoma among 1011patients aged 75 years or older : A Danish population-based cohort study", Eur J Cancer, 99, pp.86~96 (2018)
- Bataillard EJ, "Impact of R-CHOP dose intensity on survival outcomes in diffuse large B-cell lymphoma : a systematic review", Blood Adv, 5, pp.2426~2437 (2021)
- Carson KR, "Comparative effectiveness of anthracycline-containing chemotherapy in United States veterans age 80 and older with diffuse large B-cell lymphoma", J Geriatr Oncol, 6, pp.211~218 (2015)
- Isaksen KT, "A simplified frailty score predicts survival and can aid treatment-intensity decisions in older patients with DLBCL", Blood Adv, 5, pp.4771~4782 (2021)
- Vijenthira A, "Frailty in patients with newly diagnosed diffuse large B-cell lymphoma receiving curative-intent therapy : a population-based study", J Natl Compr Canc Netw, 20, pp.635~642 (2022)
- Won CW, "The development of Korean Activities of Daily Living(K-ADL)and Korean Instrumental Activities of Daily Living(K-IADL)Scale", J Korean Geriatr Soc, 6, pp.107~120 (2002)
- Charlson ME, "A new method of classifying prognostic comorbidity in longitudinal studies : development and validation", J Chronic Dis, 40, pp.373~383 (1987)
- Cheson BD, "Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma : the Lugano classification", J Clin Oncol, 32, pp.3059~3068 (2014)
- Yoo KH, "Staging and response assessment of lymphoma : a brief review of the Lugano classification and the role of FDGPET", CT, 2022, pp.57(S1), 75~78
- Camp RL, "X-tile : a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization", Clin Cancer Res, 10, pp.7252~7259 (2004)
- Harrell FE, "Regression modeling strategies", pp.63~102 (2015), Springer
- Coiffier B, "CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma", N Engl J Med, 346, pp.235~242 (2002)
- Pfreundschuh M, "Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas : a randomised controlled trial(RICOVER-60)", Lancet Oncol, 9, pp.105~116 (2008)
- Kim YR, "Risk factors for neutropenic fever in non-Hodgkin’s lymphoma patients with primary granulocyte colony-stimulating factor prophylaxis", Korean J Intern Med, 36, pp.1181~1189 (2021)
- Peyrade F, "Attenuated immunochemotherapy regimen(R-miniCHOP)in elderly patients older than 80 years with diffuse large B-cell lymphoma : a multicentre, single-arm, phase 2 trial", Lancet Oncol, 12, pp.460~468 (2011)
- Peyrade F, "Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older : an open-label, multicentre, single-arm, phase 2 trial from the LYSA group", Lancet Haematol, 4, pp.e46~e55 (2017)
- Olszewski AJ, "Mosunetuzumab monotherapy continues to demonstrate promising efficacy and durable complete responses in elderly", unfit patients with previously untreated diffuse large B-cell lymphoma, 2022, pp.140(Supplement 1), 1778~1780